Johnson & Johnson : Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma
News Release Media Contact: Christie Corbett +1 857-636-0211 Satu Glawe +49 172-294-6264 ... | June 5, 2023
Source: marketscreener.com